<DOC>
	<DOC>NCT02256150</DOC>
	<brief_summary>To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bredinin</mesh_term>
	<criteria>Patient has been diagnosed with SLE according to American College of Rheumatology (ACR) criteria in 1997; Patient who has had a kidney biopsy within 365 days prior to screening which was confirmed as class III, III+V, IV, IV+V, or V according to the pathologic classification of International Society of Nephrology/Renal Pathology Society (ISN/RPS) in 2003; Patient with 24hrurine protein ≥ 1.0g; SLEDAI &gt; 8 ; Male or female patient between 18 and 70 years (inclusive) at informed consent obtained date; Patient with body weight between 40kg and 80kg (inclusive) at screening; Patients who sign the informed consent form; Patient who had history of allergy to any investigational product (MZR, CTX) or hormone; Patient who had received accumulated dosage of CTX &gt;3g within one year prior to screening. Patient who had received immunosuppressant or Chinese traditional medicine with immunosuppressive effect within 30 days prior to screening; Patient who had received prednisone&gt;1.0mg/kg/day or equivalent dose of other oral glucocorticoid therapies within 30 days prior to screening; Patient who received other investigational drugs within 30 days prior to screening; Patient who have received plasma exchange therapy or immunoadsorption therapy within 30 days prior to screening; Patient who require pentostatin or live vaccine (not including flu vaccine); Patient who is undergoing renal replacement therapy; Patient who received kidney transplantation; Patient with malignancy; Patient with severe hypertension (SBP &gt; 160mmHg or DBP &gt; 100mmHg) which has not been effectively controlled; Patient with white blood cell count &lt;3×109/L /L(=3.0 GI/L); Patient with SCr &gt; 176.8μmol/L; Patient who has a value that is &gt; 3 times of the upper limit of normal range for AST or ALT; Patient with hepatitis B, hepatitis C or HIV infection; Patient with other serious infections; Patient who is unsuitable for participating in this study in the opinion of investigators ( e.g. uncontrolled diabetes, central nervous system lupus , lupus encephalopathy, active psychosis,osteonecrosis of the femoral head, fulminant hepatitis, peptic ulcer, etc.); Female patient who is pregnant, currently breast feeding or willing to become pregnant; Patient with any other diseases that would affect the evaluation of efficacy or safety.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>